ISSN: 2169-0138
Drug Designing: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 
Editorial
Open Access
 
Diazepine Derivative Compounds as Heat Shock Protein 90 Inhibitor in Oncology
Yusuf Tutar*
Department of Basic Sciences, Biochemistry Division, Cumhuriyet University, Turkey
Corresponding Author : Yusuf Tutar
Department of Basic Sciences
Biochemistry Division, Cumhuriyet University, Turkey
Tel: +903462191010
Email: ytutar@outlook.com
Received: May 28, 2015; Accepted: May 30, 2015; Published: June 03, 2015
Citation: Tutar Y (2015) Diazepine Derivative Compounds as Heat Shock Protein 90 Inhibitor in Oncology. Drug Des 4:e127. doi:10.4172/2169-0138.1000e127
Copyright: © 2015 Tutar Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Drug Designing: Open Access
 
Keywords
Diazepine derivative; Heat shock protein 90 inhibitor; Oncology; Biological active compounds; Nervous system disease
Heterocycles are present in the structure of many biological active compounds and marketed drugs. Diazepine ring system (Figure-1) is one of the most important members of the heterocycles and the compounds containing diazepine ring have an increasingly important role in the treatment of nervous system disease (clobazam and lofendazam) and cancer (anthramycin and DC-81) [1]. Therefore, diazepine derivatives have attracted the attention of synthetic organic chemists and drug designers for many years due to their therapeutic activities.
Heat shock protein 90 (Hsp90) is an important member of the Hsp chaperone protein family which is mainly involved in protein folding processes in cancer cells. Hsp90 consists of three conserved domains: N-terminal domain (NTD), middle domain (MD), and C-terminal domain (CTD). NTD contains ATP binding site and chaperone activity of Hsp90 depends on ATP hydrolyses energy. Cell cycle regulators (Cdk4, Cdk6), mutated and chimeric signaling proteins (p53, v-Scr, Bcr-Abl), transmembrane tyrosine kinase (Her-2, EGFR), steroid receptors (androgen, estrogen, progesterone receptors), and transcriptional factors are significant oncogenic proteins which play significant roles in tumourigenesis in cancer cells. In order to show these functions, oncoproteins are required to properly fold to their three dimensional structures and active conformation. Hsp90 is responsible for proper folding of the oncogenic client proteins for cancer cell survival. Therefore, inhibition of Hsp90 ATPase activity has been one of the important cancer treatment aspects [2,3].
In my lab, we design diazepine derivatives to develop novel Hsp90 NTD inhibitor in target specific cancer treatment. Synthesized diazepine analogs in my lab show antagonist effect on human breast cancer cell line, and bind to the NTD and inhibit ATPase process. Inhibition parameters are determined by in-vitro and in-silico methods. Diazepine derivatives are potential candidate for the development of target-specific Hsp90 inhibitors in oncology.
Since suppression of Hsp90 induces Hsp70, the lab also focuses on dual inhibition of Hsps. Hsp70 may complement Hsp90 function and inhibition of both folder macromolecules may not fold client proteins properly [3]. This mechanism drives cancer cells to apoptosis and drug designing by this strategy may provide a novel cancer therapy.
The author acknowledges TUBITAK for the support of this work (Project 114Z365)
References



Figures at a glance

Figure
Figure 1
Select your language of interest to view the total content in your interested language
Share This Article
   
 
   
 
Relevant Topics
Disc
Disc Advances in Bioavailability
Disc Adverse Effects
Disc Antibodies Drug Conjugates
Disc Antigen – Antibody Reaction
Disc Anvisa Bioequivalence
Disc Applied Biopharmaceutics
Disc BA/BE Studies
Disc Biochemical Metabolism
Disc Bioequivalence Anticancers
Disc Bioequivalence Antidiabetics
Disc Bioequivalence Antidiuretics
Disc Bioequivalence Antipsychotics
Disc Bioequivalence Cardiovascular Products
Disc Bioequivalence Study Design
Disc Bioequivalence Study Protocols
Disc Bionanoscience
Disc Biopharmaceuticals Manufacturing and Industry
Disc Biopharmaceuticals Process Validation
Disc Biopharmaceutics and Drug Disposition
Disc Biosimilars
Disc Causality Assesment
Disc Clinical Biotherapeutics
Disc Clinical Cancer Trials
Disc Clinical Drug Trial
Disc Clinical Drug Trials
Disc Clinical Pharmacists
Disc Clinical Pharmacology
Disc Clinical Pharmacovigilance
Disc Clinical Practice Guidelines
Disc Clinical Research Studies
Disc Clinical Trials
Disc Clinical Trials Data Management
Disc Clinical Trials Data Management Softwares
Disc Clinical Trials Databases
Disc Clinical Trials Europe
Disc Clinical Trials Japan
Disc Clinical Trials Management
Disc Clinical Trials Pharmacovigilance
Disc Clinical Trials USFDA
Disc Cytochrome 450 Drug Metabolism
Disc Cytotoxicity
Disc Data Auditing Methodologies
Disc Detoxification
Disc Diabetes Protocol
Disc Diabetic Trials
Disc Drug Clinical Trials
Disc Drug Delivery Systems
Disc Drug Delivery using Nanotechnology
Disc Drug Designing
Disc Drug Development
Disc Drug Discovery
Disc Drug Interaction
Disc Drug Interactions
Disc Drug Metabolism
Disc Drug Monitoring
Disc Drug Safety Survillance
Disc Drug Therapy
Disc Drug Toxicology
Disc Drug drug interaction
Disc Drug food interaction
Disc Drugs metabolised by CYP2D6
Disc Europe Pharmacovigilance
Disc European Bioequivalence
Disc Experimental Drug Trial
Disc Experts Opinion on Nanomedicine
Disc FDA Bioequivalence
Disc Fragment Based Drug Design
Disc Good Pharmacovigilance Practice
Disc HIV Clinical Trials
Disc Heat Shock Proteins
Disc Hepatic Metabolism of Drugs
Disc Implementation and Implications of Nanomedicine
Disc In Silico Methods
Disc In vitro Bioequivalence
Disc Japan Pharmacovigilance
Disc Lipid based Nanoparticles
Disc Liver Drug Metabolism
Disc Medical Literature
Disc Medical Trails/ Drug Medical Trails
Disc Medication Error
Disc Methods in Clinical Pharmacology
Disc Molecular Modeling
Disc Nanobiopharmaceuticals
Disc Nanobiopharmaceutics
Disc Nanobiotechnology
Disc Nanocars
Disc Nanocomposites
Disc Nanoelectronics
Disc Nanoemulsions
Disc Nanoengineering
Disc Nanofabrications
Disc Nanofluidics
Disc Nanohedron
Disc Nanoionics
Disc Nanolithography
Disc Nanomedical Tools in Gene Therapy
Disc Nanomedicals
Disc Nanomedicine
Disc Nanomedicine Applications
Disc Nanomedicine and Nanobiotechnology
Disc Nanomedicine in Cancer
Disc Nanomedicine in Drug Discovery
Disc Nanoparticles
Disc Nanoparticles and Biocompatibility
Disc Nanotechnology
Disc Nanothermite
Disc Nanotoxicology
Disc Nanotubes
Disc Paid Clinical Trials
Disc Paid Research Studies Market Analysis
Disc Peptidomimetic
Disc Periodic Safety Update Reports
Disc Pharma Risk Management
Disc Pharmaceutical Industry
Disc Pharmaceutical Toxicology
Disc Pharmacoeconomics
Disc Pharmacovigilance Regulatory Updates
Disc Pharmacovigilance and Risk Management
Disc Pharmacovigilance for Alternative Medicine
Disc Phase I Drug Metabolism
Disc Phase II Drug Metabolism
Disc Pilot Studies
Disc Polymeric Nanoparticle Delivery
Disc Pre-Clinical Drug Development
Disc Preclinical Trails
Disc Preclinical safety evaluation of biopharmaceuticals
Disc Protease Substrate/Inhibitor
Disc Protocol
Disc Psychiatric Studies
Disc Psychopharmacology
Disc Randomized Controlled Trials
Disc Receptor Agonist/ Antagonist
Disc Regulatory Requirements in Bioequivalence
Disc Rehabilitation Protocols
Disc Solid Lipid Nanoparticles
Disc Structure Based Drug Design
Disc Supramolecule
Disc Therapeutic Agents
Disc Toxicity of Nanomaterials
Disc UK Pharmacovigilance
Disc US Pharmacovigilance
Disc Veterinary Pharmacovigilance
Disc screening and Drug Design
 
Related Journals
Disc Nanomedicine & Biotherapeutic Discovery Journal
Disc Bioequivalence & Bioavailability Journal
Disc Clinical Pharmacology & Biopharmaceutics Journal
Disc Nanomaterials & Molecular Nanotechnology Journal
Disc Pharmaceutics & Drug Delivery Research Journal
Disc Drug Metabolism & Toxicology Journal
Disc Drug Development & Research Journal
Disc Nanomedicine & Nanotechnology Journal
Disc Clinical Trials Journal
Disc Pharmacovigilance Journal
Disc Developing Drugs Journal
 
Recommended Conferences
Disc  5th Alzheimer’s disease and Dementia Conference
September 29-October 01, 2016 London, UK
Disc  2nd Conference on Parenterals
October 24-26, 2016 Istanbul, Turkey
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version